Top

Published in:

01-10-2012 | Meta-Analysis

Meta-analysis of association studies between five candidate genes and type 2 diabetes in Chinese Han population

Authors: Chen Jing, Han Xueyao, Ji Linong

Published in: Endocrine | Issue 2/2012

Abstract

The multiple small-scale association studies of candidate genes for type 2 diabetes mellitus in the Chinese Han population have shown inconsistent results. Here, we performed a meta-analysis to evaluate the contribution of five candidate genes to the pathogenesis of type 2 diabetes in the Chinese Han population. We searched for relevant published papers and used STATA v.11.0 to perform a meta-analysis on six single-nucleotide polymorphisms in five genes—ADIPOQ-rs2241766 (SNP45) and -rs1501299 (SNP276), ADRB3-rs4994 (Trp64Arg), CAPN10-rs3792267 (SNP43), ENPP1-rs1044498 (K121Q), and PPARGC1A-rs8192678 (Gly482Ser)—in the Chinese Han population under an additive genetic model. The pooled odds ratios (95% confidence intervals and P-values) were 0.71 (0.60–0.83; P < 0.001) for ADIPOQ-rs2241766, 0.79 (0.64–0.97; P = 0.027) for ADIPOQ-rs1501299, 1.27 (1.07–1.51; P = 0.006) for ADRB3-rs4994, 0.79 (0.57–1.10; P = 0.163) for CAPN10-rs3792267, 1.41 (1.13–1.76; P = 0.003) for ENPP1-rs1044498, and 1.54 (1.34–1.81; P < 0.001) for PPARGC1A-rs8192678. There was high heterogeneity for ADIPOQ-rs2241766, ADIPOQ-rs1501299, and CAPN10-rs3792267 (I ² = 74.9, 69.4, and 75.8%, respectively), but not for ADRB3-rs4994, ENPP1-rs1044498, and PPARGC1A-rs8192678 (I ² = 0.0, 43.4, and 23.3%, respectively). Under an additive genetic model, the C allele of ADRB3-rs4994, the C allele of ENPP1-rs1044498, and the A allele of PPARGC1A-rs8192678 increase the risk of type 2 diabetes in the Chinese Han population.

M.E. Travers, M.I. McCarthy, Type 2 diabetes and obesity: genomics and the clinic. Hum. Genet. 130, 41–58 (2011)PubMedCrossRef

P.T. Higgins, G.S. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002)PubMedCrossRef

K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998)PubMedCrossRef

S. Duval, R. Tweedie, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455–463 (2000)PubMedCrossRef

T. Oizumi, M. Daimon, T. Saitoh, W. Kameda, H. Yamaguchi, H. Ohnuma, M. Lgarashi, H. Eguchi, H. Manaka, M. Tominag, T. Kato, Funagata Diabetes Study, Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the beta(3)-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. Diabetes Care 24, 1579–1583 (2001)

J. Walston, K. Silver, C. Bogardus, W.C. Knowler, F.S. Celi, S. Austin, B. Manning, A.D. Strosberg, M.P. Stern, T.N. Raben, Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the β3-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. N. Engl. J. Med. 333, 343–347 (1995)PubMedCrossRef

X. Yuan, K. Yamada, K. Koyama, F. Ichikawa, S. Ishiyama, A. Koyanagi, W. Koyama, K. Nonaka, Beta 3-adrenergic receptor gene polymorphism is not a major genetic determinant of obesity and diabetes in Japanese general population. Diabetes Res. Clin. Pract. 37, 1–7 (1997)PubMedCrossRef

R. Büettner, A. Schäffler, H. Arndt, G. Rogler, J. Nusser, B. Zietz, I. Enger, S. Hügl, A. Cuk, J. Schölmerich, K.D. Palitzsch, The Trp64Arg polymorphism of the beta 3-adrenergic receptor gene is not associated with obesity or type 2 diabetes mellitus in a large population-based Caucasian cohort. J. Clin. Endocrinol. Metab. 83, 82289–82892 (1998)

A. Scuteri, S. Sanna, W.M. Chen, M. Uda, G. Albai, J. Strait, S. Najjar, R. Nagaraja, M. Orrú, G. Usala, M. Dei, S. Lai, A. Maschio, F. Busonero, A. Mulas, G.B. Ehret, A.A. Fink, A.B. Weder, R.S. Cooper, P. Galan, A. Chakravarti, D. Schlessinger, A. Cao, E. Lakatta, G.R. Abecasis, Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. (2007). doi:10.1371/journal.pgen.0030115.eor

10.

T.M. Frayling, N.J. Timpson, M.N. Weedon, E. Zeggini, R.M. Freathy, C.M. Lindgren, J.R. Perry, K.S. Elliott, H. Lango, N.W. Rayner, B. Shields, L.W. Harries, J.C. Barrett, S. Ellard, C.J. Groves, B. Knight, A.M. Patch, A.R. Ness, S. Ebrahim, D.A. Lawlor, S.M. Ring, Y. Ben-Shlomo, M.R. Jarvelin, U. Sovio, A.J. Bennett, D. Melzer, L. Ferrucci, R.J. Loos, I. Barroso, N.J. Wareham, F. Karpe, K.R. Owen, L.R. Cardon, M. Walker, G.A. Hitman, C.N. Palmer, A.S. Doney, A.D. Morris, G.D. Smith, A.T. Hattersley, M.I. McCarthy, A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889–894 (2007)PubMedCrossRef

11.

W. Huang, Y. Sun, J. Sun, Combined effects of FTO rs9939609 and MC4R rs17782313 on obesity and BMI in Chinese Han populations. Endocrine 39, 69–74 (2011)PubMedCrossRef

12.

H. Li, T.O. Kilpeläinen, C. Liu, J. Zhu, Y. Liu, C. Hu, Z. Yang, W. Zhang, W. Bao, S. Cha, Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96551 East and South Asians. Diabetologia (2011). doi:10.1007/s00125-011-2370-7

13.

H. Dong, B.A. Maddux, J. Altomonte, M. Meseck, D. Accili, R. Terkeltaub, K. Johnson, J.F. Youngren, I.D. Goldfine, Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes 54, 367–372 (2005)PubMedCrossRef

14.

I.D. Goldfine, B.A. Maddux, J.F. Youngren, G. Reaven, D. Accili, V. Trischitta, R. Vigneri, L. Frittitta, The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocrinal. Rev. 29, 62–75 (2008)CrossRef

15.

R. Baratta, P. Rossetti, S. Prudente, F. Barbetti, D. Sudano, A. Nigro, M.G. Farina, F. Pellegrini, V. Trischitta, L. Frittitta, Role of the ENPP1 K121Q polymorphism in glucose homeostasis. Diabetes 57, 3360–3364 (2008)

16.

J.B. McAteer, S. Prudence, S. Bacci, H.N. Lyon, J.N. Hirschhorn, V. Trischitta, J.C. Florez, ENPP1 consortium: the ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 57, 1125–1130 (2008)PubMedCrossRef

17.

N. Abate, M. Chandalia, P. Satija, B. Adams-Huet, S.M. Grundy, S. Sandeep, V. Radha, R. Deepa, V. Mohan, ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes 54, 1207–1213 (2005)PubMedCrossRef

18.

J.S. Bhatti, G.K. Bhatti, S.S. Mastana, J.S. Bhatti, S. Ralhan, A. Joshi, R. Tewari, ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes in North Indians. Mol. Cell. Biochem. 345, 249–257 (2010)PubMedCrossRef

19.

S. Myles, R.A. Lea, J. Ohashi, G.K. Chambers, J.G. Weiss, E. Hardouin, J. Engelken, D.P. Macartney-Coxson, D.A. Eccles, I. Naka, R. Kimura, T. Inaoka, Y. Matsumura, M. Stoneking, Testing the thrifty gene hypothesis: the Gly482Ser variant in PPARGC1A is associated with BMI in Tongans. BMC Med. Genet. 11, 1–2 (2011). doi:10.1186/1471-2350-12-10

20.

C. Ling, S. Del Guerra, R. Lupi, T. Rönn, C. Granhall, H. Luthman, P. Masiello, P. Marchetti, L. Groop, S. Del Prato, Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 51, 615–622 (2008)PubMedCrossRef

21.

I. Barroso, J. Luan, M.S. Sandhu, P.W. Franks, V. Crowley, A.J. Schafer, S. O’Rahilly, N.J. Wareham, Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 49, 501–505 (2006)PubMedCrossRef

22.

N. Siitonen, L. Pulkkinen, J. Lindström, M. Kolehmainen, J.G. Eriksson, M. Venojärvi, P. Ilanne-Parikka, S. Keinänen-Kiukaanniemi, J. Tuomilehto, M. Uusitupa, Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med. Genet. (2011). doi:10.1186/1471-2350-12-5

23.

W. Du, Q. Li, Y. Lu, X. Yu, X. Ye, Y. Gao, J. Ma, J. Cheng, Y. Cao, J. Du, H. Shi, L. Zhou, Genetic variants in ADIPOQ gene and the risk of type 2 diabetes: a case-control study of Chinese Han population. Endocrine 40, 413–422 (2011)PubMedCrossRef

24.

C. Ling, L. Groop, S.D. Guerra, R. Lupi, Calpain-10 expression is elevated in pancreatic islets from patients with type 2 diabetes. PLoS ONE (2009). doi:10.1371/journal.pone.0006558

25.

Y. Horikawa, N. Oda, N.J. Cox, X. Li, M. Orho-Melander, Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat. Genet. 26, 163–175 (2000)PubMedCrossRef

26.

Y. Wang, L. Ling, C.L. Huang, Correlation of adiponectin gene polymorphism and type2 diabetes mellitus in Han population of Guangdong. J. Trop. Med. 7, 651–653 (2007)

27.

J.M. Hao, Z.H. Dao, J.X. Liu, Correlation between single nucleotide polymorphism of adiponectin gene and type2 diabetes in Han population. Hainan Med. 20, 1–3 (2009)

28.

Y. Wang, T. Wang, H.T. Zhong, An association research of adiponectin gene SNP45T/G polymorphism and type2 diabetes mellitus. Prog. Mod. Biomed. 8, 84–86 (2008)

29.

X.H. Shi, F. Jin, L. Sun, H. Li, L. Wang, Z. Yang, Association of the polymorphism of SNP45T/G in adiponectin gene with type 2 diabetes mellitus. J. Clin. Rehabil. Tissue Eng. Res. 11, 4941–4944 (2007)

30.

H. Ye, J. Zhuang, An association research of adiponectin gene SNP45T/G polymorphism and type2 diabetes mellitus. Prog. Mod. Biomed. 9, 158–160 (2009)

31.

Y. Dong, G. Li, T.H. Luo, G. Wu, W. Huang, M. Luo, Relationship between adiponection gene polymorphisms and type2 diabetes. Acad. J. Shanghai Second Med. Univ. 24, 1001–1003 (2004)

32.

Y.P. Li, Y.F. Yao, Y. Zhang, X.L. Li, W.Y. Tao, F. Xu, Correlation between adiponection gene polymorphisms and type2 diabetes. China J. Mod. Med. 20, 961–965 (2010)

33.

B. Zhai, L. Ye, J.W. Liu, J. Liu, Interaction of adiponectin and peroxisome proliferator activated receptor gamma2 gene polymorphisms and their relationship with type2 diabetes in population from Beijing communities. Chin. J. Clin. Rehabil. 10, 28–31 (2006)

34.

Q.J. Su, Correlation of adiponectin gene polymorphism and type 2 diabetes mellitus. Guangxi Med. Univ. (2005)

35.

Y.L. Wei, L.J. He, Z.H. Huo, SNP45 (T/G) of adiponectin gene polymorphism and genetic susceptibility to type 2 diabetes. Basic Clin. Med. 28, 940–943 (2008)

36.

Z.X. Wang, Study on Serum Adiponectin Level and Its Gene Polymorphism in Different Glucose Tolerance Humans (Hebei Medical University, Hebei, 2005)

37.

H. Xia, Y.Z. Mo, R.W. Bian, J. Shen, L.X. Ma, Correlation between single nucleotide polymorphism of adiponectin gene and type2 diabetes in Chinese. Chin. J. Endocrinol. Metab. 20, 236–237 (2004)

38.

W. Chen, H.Z. Yi, X.W. Ma, Single nucleotide polymorphism of adiponectin gene 45 site in patients with type 2 diabetes in the south of Henan province. J. Zhengzhou Univ. (Med. Sci.) 42, 1145–1147 (2007)

39.

M.F. Gu, W.J. Wu, R.F. Bu, S.W. Zhu, L. Xu, Studies on serum adiponectin level and SNP45 of adiponectin gene in patients with type 2 diabetes. J. Jiangsu Univ. (Med. Ed.) 17, 498–502 (2007)

40.

Z. Kang, C.K. Sun, H.Z. Zhao, Y.B. Sha, D.M. Yu, Correlation between polymorphism of adiponectin gene and type 2 diabetes mellitus in Bai and Han population at Dali area. Chin. J. Diabetes 16, 718–720 (2008)

41.

S.F. Wang, J.J. Zhao, Q.L. Jiang, H. Ma, The correlation between adiponectin gene polymorphism and type 2 diabetes. Chin. J. Endocrinol. Metab. 23, 51–52 (2007)

42.

Y.X. Wang, L. Zhao, S.G. Yu, C.M. Liu, Correlation of adiponectin gene polymorphism and type 2 diabetes mellitus. Shandong Med. J. 50, 1–2 (2010)

43.

H. Sun, Z.C. Gong, J.Y. Yin, H.L. Liu, Y.Z. Liu, Z.W. Guo, The association of adiponectin allele 45T/G and -11377C/G polymorphisms with type 2 diabetes and rosiglitazone response in Chinese patients. Br. J. Clin. Pharmacol. 65, 917–926 (2008)PubMedCrossRef

44.

Y. Wang, T. Wang, H.T. Zhong, An association research of adiponectin gene SNP45T/G polymorphism and type 2 diabetes mellitus. Prog. Mod. Biomed. 8, 884–886 (2008)

45.

Y.Z. Sun, Z.X. Guo, Correlation between SNP276 of adiponectin gene and type2 diabetes. Shanxi Med. J. 36, 661–663 (2007)

46.

Y. Ru, M. Ma, T. Ma, C.J. Wang, Y.M. Wang, Association of SNP276 in adiponectin gene and type2 diabetes mellitus and insulin sensitivity. Chin. J. Med. Genet. 22, 698–701 (2005)

47.

K. Wang, X.L. Xia, D.M. Liu, D.M. Yu, The association of adiponectin gene polymorphism with insulin resistance and type 2 diabetes mellitus. J. Tianjin Med. Univ. 15, 190–193 (2009)

48.

A.M. Bao, S.X. Xiao, C.J. Wang, M.G. Yang, Phenotypic characteristics of the Trp64Arg polymorphism in the beta-3-adrenergic receptor gene in type 2 diabetes and normal subjects. Chin. J. Diabetes 8, 13–16 (2000)

49.

Y. Chen, L. Zhou, Y.C. Xu, H.B. Shen, R.B. Rong, J.Y. Niu, Study on association of mutation of the B3-Adrenergic receptor gene with NIDDM. China Publ. Health 17, 586–588 (2001)

50.

Z.M. He, Q.M. Xiao, X.H. Gao, The association research of B3-Adrenergic receptor gene Trp64Argmutation and T2DM. J. Binzhou Vocat. Coll. 2, 74–76 (2005)

51.

Z.G. Hui, X.W. Zhou, X.L. Wang, W.H. Cao, L. Chen, Relationship between B3-Adrenergic receptor gene polymorphism and insulin resistance in type2 diabetes. Acta Acad. Weifang. 27, 173–175 (2005)

52.

M.L. Li, M. Wang, G.N. Yu, X.X. Lv, J.M. Zhao, The Trp64Arg variation in B3-Adrenergic receptor gene and type2 diabetes mellitus. Acta Acad. Med. Shandong 38, 57–59 (2000)

53.

Y.M. Li, J.M. Liang, Study on codon 64 in the B3-adrenergic receptor gene mutation in patients with type 2 diabetes mellitus. Acad. J. Guangzhou Med. Coll. 32, 60–62 (2004)

54.

Y.R. Sun, Z. Yang, L.N. Ji, The Trp64Arg variation in B3-adrenergic receptor gene and type2 diabetes mellitus. Chin. J. Diabetes 12, 43–44 (2004)

55.

L.L. Xiu, J.P. Weng, J. Wang, Common variants in B3-adrenergic receptor gene and uncoupling protein2 genes are associated with type2 diabetes and obesity. Nat. Med. J. Chin. 84, 375–379 (2004)

56.

X.Y. Zhang, X.M. Qian, Y.L. Ma, L.B. Kong, The genotype of B3-adrenergic receptor gene in type2 diabetes and insulin resistance. J. Jining Med. Coll. 30, 301–303 (2007)

57.

J. Dong, H.M. Peng, A case-control study on the role of calpain10 gene single nucleotide polymorphism in the genetic susceptibility to type 2 diabetes mellitus in the genetic susceptibility to type 2 diabetes mellitus in southern Chinese Han population. J. Chongqing Med. Univ. 33, 1475–1478 (2008)

58.

H.X. Zhang, K.X. Zhang, W.N. Du, J.X. Shi, Z.W. Jiang, J. Zuo, Single nucleotide polymorphism in CAPN10 gene of Chinese population and its correlation with type 2 diabetes mellitus in Han people of Northern China. Acad. Med. Sci. 24, 229–233 (2002)

59.

R.M. Zhang, B.Y. Xu, J. Qiu, A case-control study on role of calpain10 gene polymorphism in the genetic susceptibility to type2diabetes in plateau population in Kunming. Chin. J. Prev. Chron. Non-Commun. Dis. 13, 263–265 (2005)

60.

D. Wang, J.J. Chen, L. Yu, X.M. Deng, Y. Wang, X. Chen, Single nucleotide polymorphism43 in CAPN10 gene and its correlation with type 2 diabetes mellitus. Shandong Med. J. 48, 54–55 (2008)

61.

J.E. Li, D.M. Liu, Z. Zhang, Study on the relationship between the gene polymorphism of CAPN10 and the resistance of T2D. Tianjin Med. J. 36, 96–98 (2008)

62.

Q. Zhou, Role of calpain10 gene polymorphism in genetic susceptibility in type2 diabetes mellitus in Chinese Han population. J. Wannan Med. Univ. 27, 246–249 (2008)

63.

L.N. Ji, L.X. Chen, X.Y. Han, F. Zhu, The role of calpain10 gene polymorphism in the genetic susceptibility to type2 diabetes in Chinese population. Chin. J. Diabetes 10, 7–10 (2002)

64.

D. Wang, B.L. Su, C.C. Li, J.L. Du, R. Bai, Y. Yang, Genetic variation of SNP43 in calpain 10 gene is not a major factor in the pathogenesis of type 2 diabetes and insulin resistance in Chinese. Chin. J. Diabetes 13, 190–191 (2005)

65.

Y.C. Li, Z.H. Huo, W. Zhao, Z. Yang, Correlation between calpain10 polymorphism and genetic susceptibility in type 2 diabetes mellitus. Clin. Foc. 20, 12–15 (2005)

66.

K.S. Xiang, T.S. Zheng, W.P. Jia, Y.Q. Wang, K.X. Shen, J. Li, The impact of polymorphism of calpain gene on glucose intolerance status, insulin secretion and insulin sensitivity. Chin. J. Endocrinal. Metab. 17, 290–294 (2007)

67.

H.Q. Gong, R.M. Zhang, J. Qiu, Y.T. Li, Z.M. Yan, Z. Yang, Correlation study of calpain10 gene polymorphism with genetic susceptibility to type2 diabetes. Chin. J. Publ. Health 21, 1372–1374 (2005)

68.

Y.H. Cai, Q.W. Yin, Z.Y. Ding, The association of type 2diabetes and diabetes with the metabolic abnormalities and PC-1geneK121Q. China Pract. Med. 2, 24 (2007)

69.

L. Gao, M.L. Liu, S.T. Wu, Y.W. Zhong, Studies on the polymorphism of PC gene and its relationship with type 2 diabetes among Chinese population in Shenzhen areas. J. Trop. Med. 8, 553–555 (2008)

70.

C.X. Lan, M.Y. Liu, L.Y. Shen, Relationship between K121Q variant in PC gene and type 2 diabetes with early nephropathy. Med. Lab. Sci. Clin. 19, 20–22 (2008)

71.

M.R. Li, Y.B. Wu, H. Liu, Y.M. Wang, X.D. Feng, P. Dian, Correlative study of K121Q polymorphism of the PC- 1 gene with type 2 diabetes and diabetic nephropathy. J. Kunm. Med. Univ. 1, 27–31 (2008)

72.

M.L. Liu, S.T. Wu, Z.X. Lu, Correlative study of K121Q polymorphism of PC-1 gene with type 2 diabetes and diabetic nephropathy. Chin. J. Chron. Diabetes 4, 44–48 (2005)

73.

C. Peng, Q.Y. Huang, H.T. Huang, Correlative study of K121Q polymorphism of PC-1 gene with type 2 diabetes. Huazhong Normal Univ. J. Postgr. 15, 166–169 (2008)

74.

W. Ren, S.H. Zhang, J. Wu, Y.X. Ni, Q.M. Li, The K121Q polymorphism of membrane glycoprotein in PC-1 gene in pedigrees of type 2 diabetes. Chin. J Diabetes 12, 246–249 (2004)

75.

X.H. Shi, Y. Yang, L. Sun, L. Wang, F. Jin, Association study of K121Q variant in PC-1 gene with type 2 diabetes in old age population. Chin. Aged Health Care Med. J. 6, 3–6 (2008)

76.

M. Wang, C. Peng, Y.L. Qu, Q.Y. Huang, Association and meta-analysis of ENPP1 K121Q with type2 diabetes. Hereditas (Beijing). 32, 808–816 (2010)CrossRef

77.

M. Xu, D.Q. Wang, L. Xu, X.K. Tang, Y.G. Tang, Association of membrane glycoprotein PC-1 gene K121Q polymorphism with type 2 diabetes. Chin. J. Endocrinol. Metab. 19, 390–391 (2003)

78.

Y.C. Xu, Z. Li, J.H. Li, X.H. Teng, C. Wang, M. Zhao, Relationship of K121Q variant in PC21 gene with type 2 diabetes mellitus. Lab. Med. 20, 313–316 (2005)

79.

L. Zhang, L.L. Lv, H. Sang, N. Wang, N.N. Yang, Association of ENPP1 gene K121Q polymorphism with type 2 diabetes in Taian population. J. Taishan Med. Coll. 31, 109–111 (2010)

80.

Y.W. Zhong, L. Gao, S.T. Wu, Y.J. Geng, Y.X. Yu, Investigation into the relationship of membrane glycoprotein gene polymorphism with type2 diabetes. China Trop. Med. 6, 2113–2114 (2006)

81.

Y.C. Hui, Y.F. Guan, Z. Li, W. Sun, X. Zhang, P. Zhang, B.L. Su, Association of peroxisome proliferator activated receptor-γ coactivator (PGC1a) Gly482Ser polymorphism with type 2diabetes. J. Dalian Med. Univ. 31, 295–298 (2009)

82.

W.S. Lu, Y. Cheng, Q. Huang, L. Yan, C.G. Chen, L.Q. Qi, M.C. Wu, F. Li, Screening the PGC1a gene for SNPs and analyzing PGC1a Gly482Ser mutation in Chinese population. Chin J Diabetes 14, 192–194 (2006)

83.

L. Shan, C. Wang, L.N. Ji, Z. Yang, Q. Zhu, Association of PGC1 gene Gly482Ser polymorphism with type 2 diabetes. Chin J Diabetes 14, 103–105 (2006)

84.

X.H. Wang, K.J. Yang, Z.B. Zhang, X.J. Jin, Y.H. Jin, M.H. Jin, Association of PGC1 gene Gly482Ser polymorphism with type 2 diabetes. J. Med. Sci. Yanbian Univ. 27, 83–89 (2004)

85.

Y.B. Wang, Y.C. Yu, Z. Li, C. Wang, J.Y. Wang, G.T. Wu, Study on the relationship between polymorphisms of peroxisome proliferator activated receptor-C coactivator -1a gene and type2 diabetes in Shanghai Hans in China. Chin. J. Med. Genet. 22, 453–456 (2005)

86.

S.L. Zhang, W.S. Lu, L. Yang, Association between peroxisome proliferator-activated receptor-γ coactivator-1α gene polymorphisms and type2 diabetes in southern Chinese population: role of altered interaction with myocyte enhancer factor 2C. Chin. Med. 120, 1878–1885 (2007)

Title: Meta-analysis of association studies between five candidate genes and type 2 diabetes in Chinese Han population
Authors: Chen Jing
Han Xueyao
Ji Linong
Publication date: 01-10-2012
Publisher: Springer US
Published in: Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9643-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

The incidence and prevalence of thyroid autoimmunity

Synchronous thyroid and gastric diffuse large B-cell lymphoma

Growth hormone deficiency and cardiovascular risk: do we need additional markers?

Clinical–pathological changes in differentiated thyroid cancer (DTC) over time (1997–2010): data from the University Hospital “Maggiore della Carità” in Novara

Effects of prolonged exercise on agouti-related protein: a pilot study

Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials